<unk> , sold under the brand name Evusheld is a combination of two human monoclonal antibodies,<unk>  (AZD8895) and<unk>  (AZD1061) targeted against the surface spike protein of SARS-CoV-2 used to prevent COVID-19. It is being developed by British-Swedish multinational pharmaceutical and biotechnology company AstraZeneca. It is co-packaged and given as two separate consecutive intramuscular injections (one injection per monoclonal antibody, given in immediate succession).
Tixagevimab/cilgavimab
Casirivimab/imdevimab
Bamlanivimab/etesevimab
Atoltivimab/maftivimab/odesivimab
Obiltoxaximab
Odesivimab
Regdanvimab
Lirentelimab